The Institute for Neurological Research has developed a medical breakthrough for the treatment of disc-related pain
The Institute for Neurological Research® has invented and pioneered new therapeutic approaches for a variety of neurological disorders with widespread unmet medical need. The INR's accomplishments are not limited to the treatment of disc-related pain. The INR's research has also been in the field of dementia and Alzheimer's disease.
The INR has published its findings in multiple, peer-reviewed medical journals, including BMC Neurology, Clinical Therapeutics, Drug Discovery Today, and Current Medical Research and Opinion. INR publications, findings, and research have advanced the science of neurology, dementia, and spine medicine, and have been cited and discussed by physicians and scientists from academic centers around the world. In 2008 alone there were more than 45 scientific citations to INR publications, including in Nature Clinical Practice Neurology and F1000 Biology.
The INR has presented its scientific findings at multiple U.S. and international medical and scientific conferences, including at the Karolinska Institute in Sweden; the 2008 Drug Repositioning Summit in Boston; the International Conference on Alzheimer's Disease in Chicago; the 7th Annual Alzheimer's Drug Discovery Conference in New York; the 2009 Restauracion Neurologica Conference in Havana, Cuba; and the University of Arkansas Medical Sciences in Little Rock, Arkansas. Invited presentations at the World Pharmaceutical Congress in Philadelphia in June 2009 and the 5th Modern Drug Discovery Conference in October 2009 in San Diego are scheduled.
The INR has performed collaborative research with scientists from Stanford University School of Medicine and the University of British Columbia in Vancouver.
Edward Tobinick MD, Director of the INR, is an Assistant Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA and a member of the Editorial Board of the Journal of Neuroinflammation. In 2009 he has been an invited expert reviewer for the medical journals Neuroscience, Experimental Neurology, and Brain Research.
Full-text or summaries
of the following INR publications are available by clicking
on the images below:
INR
collaboration with Stanford: Tobinick,
E.L., K. Chen, and X. Chen, Rapid
intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral
administration demonstrated by PET imaging. BMC Res Notes,
2009. 2: p. 28. full-text
PDF
Tobinick, E., Perispinal
etanercept for neuroinflammatory disorders. Drug Discovery
Today, 2009. 14(3-4): p. 168-77. (Abstract
PDF)
Tobinick, E. and S. Davoodifar, Efficacy
of etanercept delivered by perispinal administration for chronic
back and/or neck disc-related pain: a study of clinical observations
in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85.
(Abstract PDF)
Tobinick,
E.L. and H. Gross, Rapid
improvement in verbal fluency and aphasia following perispinal
etanercept in Alzheimer's disease. BMC Neurology, 2008.
8: p. 27. (Abstract
PDF)
U.S. patent 6,419,944, filed April 5, 2001; also
6,537,549; and 6,982,089, issued to Edward Tobinick MD and assigned
to TACT IP, LLC; and additional patents and related applications,
assigned to TACT IP, LLC.
Tobinick, E.L. and S.
Britschgi-Davoodifar, Perispinal
TNF-alpha inhibition for discogenic pain. Swiss Med Wkly,
2003. 133(11-12): p. 170-7. (Abstract
PDF)
Tobinick, E.L., Targeted etanercept
for discogenic neck pain. Clin Ther, 2003. 25(4): p. 1211-8.
(Abstract PDF)
Tobinick,
E., The value of drug repositioning in the current pharmaceutical
market. Drug News and Perspectives 2009 Mar-Apr 22(2). (Abstract PDF)
Additional
References
9. Cohen, S.P., N. Bogduk, A.
Dragovich, C.C. Buckenmaier, 3rd, S. Griffith, C. Kurihara, J.
Raymond, P.J. Richter, N. Williams, and T.L. Yaksh, Randomized,
double-blind, placebo-controlled, dose-response, and preclinical
safety study of transforaminal epidural etanercept for the treatment
of sciatica. Anesthesiology, 2009. 110(5): p. 1116-26.
10. Kato, K., S. Kikuchi, V.I. Shubayev, and R.R. Myers, Distribution
and tumor necrosis factor-alpha isoform binding specificity of
locally administered etanercept into injured and uninjured rat
sciatic nerve. Neuroscience, 2009. 160(2): p. 492-500.
11. Zanella, J.M., E.N. Burright, K. Hildebrand, C. Hobot, M.
Cox, L. Christoferson, and W.F. McKay, Effect of etanercept,
a tumor necrosis factor-alpha inhibitor, on neuropathic pain in
the rat chronic constriction injury model. Spine, 2008. 33(3):
p. 227-34.
12. Genovese, T., E. Mazzon, C. Crisafulli, R. Di Paola, C. Muia,
P. Bramanti, and S. Cuzzocrea, Immunomodulatory effects of
etanercept in an experimental model of spinal cord injury.
J Pharmacol Exp Ther, 2006. 316(3): p. 1006-16.
13. Myers, R.R., W.M. Campana, and V.I. Shubayev, The role
of neuroinflammation in neuropathic pain: mechanisms and therapeutic
targets. Drug Discov Today, 2006. 11(1-2): p. 8-20.
14. Olmarker, K. and B. Rydevik, Selective inhibition of tumor
necrosis factor-alpha prevents nucleus pulposus-induced thrombus
formation, intraneural edema, and reduction of nerve conduction
velocity: possible implications for future pharmacologic treatment
strategies of sciatica. Spine, 2001. 26(8): p. 863-9.
15. Sommer, C. and M. Schafers, Mechanisms of neuropathic pain:
the role of cytokines. Drug Discovery Today: Disease Mechanisms,
2004. 1(4): p. 441-448.
16. Sommer, C., M. Schafers, M. Marziniak, and K.V. Toyka, Etanercept
reduces hyperalgesia in experimental painful neuropathy. J
Peripher Nerv Syst, 2001. 6(2): p. 67-72.
